Suggestions
David Shapiro
Chief Executive Officer - Google Partner - Facebook Partner - HubSpot Certified - LinkedIn Certified - Series 79 Registered Investment Banker
David Shapiro is a seasoned professional with over 20 years of experience in marketing, technology, and finance. He has held significant roles in various organizations including global banks, ad agencies, and consulting firms. His expertise lies in the convergence of marketing, finance, and technology, which he terms as 'mar-fin-tech'. David is a Google Partner, Series 79 FINRA Registered Investment Banking Representative, Facebook Marketing Partner, LinkedIn Marketing Certified, and holds multiple HubSpot Academy Certifications. He has completed over 250 courses on Google Skillshop and earned 19 Salesforce Trailhead Badges.
David's hands-on experience includes managing and optimizing Google Ads, Facebook Ad accounts, and paid ad campaigns with substantial budgets. He leverages CRM and marketing automation to measure the real ROI on marketing efforts. His consulting services cater to a wide range of industries including healthcare, consumer products, biotech, travel, hospitality, pharmaceutical, and financial services. As the CEO of b2i digital, David is well-versed in all aspects of digital marketing, providing valuable insights and solutions to his clients.
David's educational background comprises New York State High School Regents Diploma, a B.S. in Applied Economics and Business Management from Cornell University, and ongoing self-study in digital marketing, sales, and CRM technologies. Throughout his career, David has held executive positions in various companies, demonstrating his diverse skill set and expertise in marketing, technology, and finance.
Having served as Chief Marketing Officer at Maxim Group and M-Vest, along with leadership roles in other prominent organizations, David is a reputable figure in the digital marketing industry. He has exceptional proficiency in managing ad campaigns, analyzing data, and providing strategic marketing solutions. His commitment to continuous learning and daily study sets him apart in understanding and navigating the ever-evolving digital landscape.
Highlights
ROTH Capital Partners (ROTH MKM) 36th Annual Conference Recap:
The event saw over 3,700 people come together for two packed days of over 5,500 1x1 meetings, 440 participating companies, 30-panel discussions, and 140 analyst-moderated fireside chats.
The event started with a weekend of charity events, raising over $100,000 for the Challenged Athletes Foundation. In addition, in partnership with RX3 Growth Partners and with the help of 8 National Football League (NFL) quarterbacks, 110 players, and almost 1,400 charity attendees, nearly $3M was raised for local and national charities.
The event also featured two evenings of entertainment, including Vegas resident Dj Marshmello and Nate Smith’s gritty backwoods soul and rock & roll.
B2i Digital profiled participating companies on our website at https://lnkd.in/e_6Ds_Hf and shared them across social channels with our community of 679,304 institutional and retail investors.
- LinkedIn (B2i Digital)
- Facebook (https://lnkd.in/g8-JQrdC)
- Instagram (https://lnkd.in/gez5Khdr)
- X/Twitter (https://lnkd.in/gc_5QfQn)
- Threads (https://lnkd.in/gzjDwPVZ)
It's impossible to tag everyone involved with this mega-event, but here are a few.
Isabel Mattson-Pain, Sagar Sheth, Amanda McAdams, Alexander Montano, Otilia "Charo" Montano, Paul Zaffaroni, Blair Friedensohn, Ivan S., Benjamin Bowen, Craig Irwin, Steven L. Messina, Jeff Martin, Matt Koranda, Thomas R Schwartz, Jesse P., George Kelly, CFA, Suji DeSilva, Robert Stephenson, Al Longfield, James Antonopoulos, Jacob Frank, Doug Gonsalves, Sean Leahy, Ben Healy, Greg Kouvelas, Samir Hussein, Brady Fletcher, Gil Ottensoser, Greg Ogborn, David Farina, Rohit Kulkarni, John O'Brien, Gerald Mars.
Stay tuned for details for the 37th Annual Roth Conference in March 2025.
Our B2i Digital featured company, Jaguar Health (NASDAQ: JAGX), announced they have signed an exclusive licensing and commercialization agreement with Turkish pharmaceutical company GEN for crofelemer, Jaguar’s novel plant-based, FDA-approved drug. See their Featured Company profile here: https://lnkd.in/exkQ2dbF
The deal includes a $2M investment by GEN in Jaguar stock at a 75% premium and double-digit royalty payments to Jaguar on crofelemer sales.
The agreement covers Jaguar’s Mytesi, approved for HIV-related diarrhea, and potential follow-on indications like cancer therapy-related diarrhea (currently in Phase 3) and rare diseases like short bowel syndrome.
According to the press release, GEN gains rights to manufacture and sell crofelemer in Turkey and eight neighboring countries after receiving regulatory approvals.
Jaguar CEO Lisa Conte stated: “We are very happy about the commitment Jaguar and GEN have made to enter an exclusive license and commercialization agreement. This initiative underscores Jaguar’s mission and common vision with GEN to provide patients around the world with access to prescription pharmaceuticals for essential supportive care and management of neglected symptoms across multiple complicated disease states such as cancer, SBS, and MVID.”
The full release is available here: https://lnkd.in/ghA2b2Z5
B2i Digital is pleased to showcase Jaguar’s continued progress. This agreement exemplifies the tireless efforts of CEO Lisa Conte, Chief Scientific Officer Pravin Chaturvedi, Chief Medical Officer Dr. Darlene P. Horton, MD , EVP Dr. Dr. Karen J. Brunke , VP of Investor Relations Peter C. H., and the entire Jaguar team to advance treatments for overlooked conditions.
Stay updated on Jaguar Health and the company’s latest news here: https://lnkd.in/e82X-Cd5
#biotech #pharma #raredisease #clinicaltrials #healthtech #B2iDigital #JaguarHealth #Ethnobotany #RainforestPlants #animalhealth #plantbased #orphandiseases #PharmaceuticalTechnology
